Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivan Borrello

Showing results (61-70 of 82) with videos related to

Pageof 9
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 21, 2020
Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation CyclophosphamideAmy E DeZern, Hany Elmariah, Marianna Zahurak, et al.
Blood Advances|April 29, 2020
Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamideAmy E DeZern, Marianna L Zahurak, Heather J Symons, et al.
Blood Advances|August 20, 2020
Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adultsHeather J Symons, Marianna Zahurak, Yilin Cao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2015
Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinomaJoseph A Califano, Zubair Khan, Kimberly A Noonan, et al.
Transplantation and Cellular Therapy|August 23, 2021
Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation CyclophosphamideKatherine C Rappazzo, Marianna Zahurak, Maria Bettinotti, et al.
The New England Journal of Medicine|December 9, 2014
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphomaStephen M Ansell, Alexander M Lesokhin, Ivan Borrello, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2018
Correction: Tadalafil Augments Tumor-specific Immunity in Patients with Head and Neck Squamous Cell CarcinomaJoseph A Califano, Zubair Khan, Kimberly A Noonan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 18, 2018
Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not OutcomesShannon R McCurdy, Stephen T Muth, Hua-Ling Tsai, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 21, 2009
Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcomeYvette L Kasamon, Leo Luznik, Mary S Leffell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib StudyAlexander M Lesokhin, Stephen M Ansell, Philippe Armand, et al.
Pageof 9

Showing results (61-70 of 82) with videos related to

Sort By:
Pageof 9
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 21, 2020
Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation CyclophosphamideAmy E DeZern, Hany Elmariah, Marianna Zahurak, et al.
Blood Advances|April 29, 2020
Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamideAmy E DeZern, Marianna L Zahurak, Heather J Symons, et al.
Blood Advances|August 20, 2020
Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adultsHeather J Symons, Marianna Zahurak, Yilin Cao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2015
Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinomaJoseph A Califano, Zubair Khan, Kimberly A Noonan, et al.
Transplantation and Cellular Therapy|August 23, 2021
Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation CyclophosphamideKatherine C Rappazzo, Marianna Zahurak, Maria Bettinotti, et al.
The New England Journal of Medicine|December 9, 2014
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphomaStephen M Ansell, Alexander M Lesokhin, Ivan Borrello, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2018
Correction: Tadalafil Augments Tumor-specific Immunity in Patients with Head and Neck Squamous Cell CarcinomaJoseph A Califano, Zubair Khan, Kimberly A Noonan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 18, 2018
Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not OutcomesShannon R McCurdy, Stephen T Muth, Hua-Ling Tsai, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 21, 2009
Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcomeYvette L Kasamon, Leo Luznik, Mary S Leffell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib StudyAlexander M Lesokhin, Stephen M Ansell, Philippe Armand, et al.
Pageof 9